is senior vice-president, clinical and translational medicine at Cerevance, Inc.

David Margolin, MD, PhD

Schizophrenia can be accompanied by significant cognitive impairments. In this Mental Health Minute, Dr Margolin discusses the results of a Phase 1b clinical trial of a drug meant to treat these issues.

The drug in question, Cerevance's investigational compound CVN058, significantly improved biomarkers of cognitive impairments in patients suffering from schizophrenia. Dr Margolin discusses the structure of the drug trial, details the science behind the drug itself, and previews the next steps of his research.

Videos

A recent drug trial yields encouraging results. 

David Margolin, MD, PhD

Articles

Treating Cognitive Impairment in Patients with Schizophrenia